# Vertex, Inc.: financial statements, quarterly

VERX · Nasdaq · CIK 1806837 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/verx.md) · [Financials](/companies/verx/financials.md) · [Filings](/companies/verx/filings.md) · [Insiders](/companies/verx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/verx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [145](/filings/0001558370-24-014659.md) | [155 d](/filings/0001104659-26-019165.md) | [157](/filings/0001558370-25-006757.md) | [161](/filings/0001558370-25-010549.md) | [170](/filings/0001104659-25-105582.md) | [178 d](/filings/0001104659-26-019165.md) | [177](/filings/0001104659-26-057207.md) | [185](/filings/0001104659-26-090420.md) | [192](/filings/0001104659-25-105582.md) | [195 d](/filings/0001104659-26-019165.md) | [197](/filings/0001104659-26-057207.md) | [204](/filings/0001104659-26-090420.md) |
| Cost of revenue | $m | [56.9](/filings/0001558370-24-014659.md) | [61.3 d](/filings/0001104659-26-019165.md) | [61.0](/filings/0001558370-25-006757.md) | [58.4](/filings/0001558370-25-010549.md) | [59.9](/filings/0001104659-25-105582.md) | [61.3 d](/filings/0001104659-26-019165.md) | [64.1](/filings/0001104659-26-057207.md) | [63.4](/filings/0001104659-26-090420.md) | [70.8](/filings/0001104659-25-105582.md) | [68.6 d](/filings/0001104659-26-019165.md) | [71.8](/filings/0001104659-26-057207.md) | [72.7](/filings/0001104659-26-090420.md) |
| Gross profit | $m | [88.2](/filings/0001558370-24-014659.md) | [93.6 d](/filings/0001104659-26-019165.md) | [95.8](/filings/0001558370-25-006757.md) | [103](/filings/0001558370-25-010549.md) | [111](/filings/0001104659-25-105582.md) | [117 d](/filings/0001104659-26-019165.md) | [113](/filings/0001104659-26-057207.md) | [121](/filings/0001104659-26-090420.md) | [121](/filings/0001104659-25-105582.md) | [126 d](/filings/0001104659-26-019165.md) | [125](/filings/0001104659-26-057207.md) | [131](/filings/0001104659-26-090420.md) |
| Research and development | $m | [16.8](/filings/0001558370-24-014659.md) | [12.9 d](/filings/0001104659-26-019165.md) | [16.8](/filings/0001558370-25-006757.md) | [14.6](/filings/0001558370-25-010549.md) | [15.6](/filings/0001104659-25-105582.md) | [19.6 d](/filings/0001104659-26-019165.md) | [20.9](/filings/0001104659-26-057207.md) | [20.6](/filings/0001104659-26-090420.md) | [19.9](/filings/0001104659-25-105582.md) | [22.3 d](/filings/0001104659-26-019165.md) | [24.6](/filings/0001104659-26-057207.md) | [24.8](/filings/0001104659-26-090420.md) |
| Operating income | $m | [(2.0)](/filings/0001558370-24-014659.md) | [(2.5) d](/filings/0001104659-26-019165.md) | [(1.6)](/filings/0001558370-25-006757.md) | [7.5](/filings/0001558370-25-010549.md) | [4.9](/filings/0001104659-25-105582.md) | [(13.1) d](/filings/0001104659-26-019165.md) | [4.5](/filings/0001104659-26-057207.md) | [(3.9)](/filings/0001104659-26-090420.md) | [4.3](/filings/0001104659-25-105582.md) | [(2.6) d](/filings/0001104659-26-019165.md) | [(10.6)](/filings/0001104659-26-057207.md) | [(4.4)](/filings/0001104659-26-090420.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.8](/filings/0001558370-24-014659.md) | [(21.8) d](/filings/0001104659-26-019165.md) | [(4.5)](/filings/0001558370-25-006757.md) | [2.2](/filings/0001558370-25-010549.md) | [0.6](/filings/0001104659-25-105582.md) | [56.4 d](/filings/0001104659-26-019165.md) | [(5.1)](/filings/0001104659-26-057207.md) | [(1.7)](/filings/0001104659-26-090420.md) | [1.5](/filings/0001104659-25-105582.md) | [5.6 d](/filings/0001104659-26-019165.md) | [(7.1)](/filings/0001104659-26-057207.md) | [(13.1)](/filings/0001104659-26-090420.md) |
| Net income | $m | [(3.4)](/filings/0001558370-24-014659.md) | [15.3 d](/filings/0001104659-26-019165.md) | [2.7](/filings/0001104659-25-105582.md) | [5.2](/filings/0001104659-25-105582.md) | [7.2](/filings/0001104659-25-105582.md) | [(67.8) d](/filings/0001104659-26-019165.md) | [11.1](/filings/0001104659-26-090420.md) | [(1.0)](/filings/0001104659-26-090420.md) | [4.0](/filings/0001104659-25-105582.md) | [(7.0) d](/filings/0001104659-26-019165.md) | [(2.5)](/filings/0001104659-26-090420.md) | [9.0](/filings/0001104659-26-090420.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [49.5](/filings/0001558370-24-014659.md) | [68.2](/filings/0001104659-26-019165.md) | [56.1](/filings/0001558370-25-006757.md) | [326](/filings/0001558370-25-010549.md) | [279](/filings/0001104659-25-105582.md) | [296](/filings/0001104659-26-019165.md) | [270](/filings/0001104659-26-057207.md) | [284](/filings/0001104659-26-090420.md) | [314](/filings/0001104659-25-105582.md) | [314](/filings/0001104659-26-090420.md) | [252](/filings/0001104659-26-057207.md) | [230](/filings/0001104659-26-090420.md) |
| Current assets | $m | [238](/filings/0001558370-23-018619.md) | [267](/filings/0001558370-25-001820.md) | [267](/filings/0001544784-24-000042.md) | [515](/filings/0001558370-24-011378.md) | [477](/filings/0001558370-24-014659.md) | [536](/filings/0001104659-26-019165.md) | [505](/filings/0001558370-25-006757.md) | [503](/filings/0001558370-25-010549.md) | [519](/filings/0001104659-25-105582.md) | [561](/filings/0001104659-26-090420.md) | [489](/filings/0001104659-26-057207.md) | [492](/filings/0001104659-26-090420.md) |
| Total assets | $m | [720](/filings/0001558370-23-018619.md) | [760](/filings/0001558370-25-001820.md) | [756](/filings/0001544784-24-000042.md) | [1,024](/filings/0001558370-24-011378.md) | [1,191](/filings/0001558370-24-014659.md) | [1,167](/filings/0001104659-26-019165.md) | [1,154](/filings/0001558370-25-006757.md) | [1,198](/filings/0001558370-25-010549.md) | [1,222](/filings/0001104659-25-105582.md) | [1,271](/filings/0001104659-26-090420.md) | [1,214](/filings/0001104659-26-057207.md) | [1,210](/filings/0001104659-26-090420.md) |
| Current liabilities | $m | [433](/filings/0001558370-23-018619.md) | [441](/filings/0001558370-25-001820.md) | [443](/filings/0001544784-24-000042.md) | [439](/filings/0001558370-24-011378.md) | [458](/filings/0001558370-24-014659.md) | [537](/filings/0001104659-26-019165.md) | [513](/filings/0001558370-25-006757.md) | [506](/filings/0001558370-25-010549.md) | [516](/filings/0001104659-25-105582.md) | [575](/filings/0001104659-26-090420.md) | [567](/filings/0001104659-26-057207.md) | [564](/filings/0001104659-26-090420.md) |
| Total liabilities | $m | [500](/filings/0001558370-23-018619.md) | [507](/filings/0001558370-25-001820.md) | [506](/filings/0001544784-24-000042.md) | [791](/filings/0001558370-24-011378.md) | [932](/filings/0001558370-24-014659.md) | [987](/filings/0001104659-26-019165.md) | [954](/filings/0001558370-25-006757.md) | [950](/filings/0001558370-25-010549.md) | [957](/filings/0001104659-25-105582.md) | [1,012](/filings/0001104659-26-090420.md) | [968](/filings/0001104659-26-057207.md) | [969](/filings/0001104659-26-090420.md) |
| Long-term debt | $m | [44.9](/filings/0001558370-23-018619.md) | [44.1](/filings/0001558370-25-001820.md) | [43.5](/filings/0001544784-24-000042.md) | [334](/filings/0001558370-24-011378.md) | [335](/filings/0001558370-24-014659.md) | [335](/filings/0001104659-26-019165.md) | [336](/filings/0001558370-25-006757.md) | [336](/filings/0001558370-25-010549.md) | [337](/filings/0001104659-25-105582.md) | [337](/filings/0001104659-26-090420.md) | [338](/filings/0001104659-26-057207.md) | [339](/filings/0001104659-26-090420.md) |
| Current portion of debt | $m | [2.5](/filings/0001558370-23-018619.md) | [2.5](/filings/0001558370-25-001820.md) | [2.5](/filings/0001544784-24-000042.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [220](/filings/0001558370-23-018619.md) | [253](/filings/0001104659-26-019165.md) | [250](/filings/0001104659-25-105582.md) | [233](/filings/0001104659-25-105582.md) | [259](/filings/0001104659-25-105582.md) | [179](/filings/0001104659-26-090420.md) | [200](/filings/0001104659-26-090420.md) | [248](/filings/0001104659-26-090420.md) | [264](/filings/0001104659-25-105582.md) | [259](/filings/0001104659-26-090420.md) | [247](/filings/0001104659-26-090420.md) | [241](/filings/0001104659-26-090420.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [27.6 d](/filings/0001558370-24-014659.md) | [47.6 d](/filings/0001104659-26-019165.md) | [24.6](/filings/0001558370-25-006757.md) | [57.7 d](/filings/0001558370-25-010549.md) | [41.4 d](/filings/0001104659-25-105582.md) | [41.1 d](/filings/0001104659-26-019165.md) | [14.8](/filings/0001104659-26-057207.md) | [46.0 d](/filings/0001104659-26-090420.md) | [62.5 d](/filings/0001104659-25-105582.md) | [42.3 d](/filings/0001104659-26-019165.md) | [38.0](/filings/0001104659-26-057207.md) | [30.9 d](/filings/0001104659-26-090420.md) |
| Capital expenditure | $m | [13.5 d](/filings/0001558370-23-018619.md) | [13.9 d](/filings/0001558370-24-002192.md) | [14.4](/filings/0001544784-24-000042.md) | [(8.4) d](/filings/0001558370-25-010549.md) | [65.7 d](/filings/0001104659-25-105582.md) | [0.0 d](/filings/0001104659-26-019165.md) | not reported | not reported | not reported | not reported | [22.0](/filings/0001104659-26-057207.md) | [0.0 d](/filings/0001104659-26-090420.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [20.0](/filings/0001104659-26-057207.md) | [26.6 d](/filings/0001104659-26-090420.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment, us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

Shares outstanding: 26,359,623 at 2020-08-31, from the cover of the [10-Q filed 2020-09-11](/filings/0001104659-20-104404.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.